However, such patients with EGFR-T790M-mutant NSCLC were expected to have other diverse resistance mechanisms that indicate the various responses to osimertinib because of the increase in intratumor heterogeneity during initial EGFR-TKI treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.